After long road, Lilly amyloid detection agent crosses US finish line
This article was originally published in Scrip
Executive Summary
After initially being rejected last year by the US FDA, Lilly's non-therapeutic radiopharmaceutical Amyvid (florbetapir F 18 injection) gained regulators blessing to enter the US market as a brain imaging agent of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.